-
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
25 Apr 2024 12:30 GMT
… overall survival (OS) rate for malignant glioma patients is less than 10% …
-
FDA grants Day One’s Ojemda accelerated approval for paediatric low-grade glioma
25 Apr 2024 11:31 GMT
… the US regulator to treat malignant glioma, as well as from the …
-
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
23 Apr 2024 19:56 GMT
… FDA for the treatment of malignant glioma and from the European Commission …
-
Recurrent Malignant Glioma Market to Reach US$ 2.2 Billion by 2034, at CAGR of 4.15% from 2024 to 2034, IMARC Group
17 Jan 2024 10:39 GMT
… malignant-glioma-market/requestsample
Recurrent Malignant Glioma Market Trends:
Recurrent malignant glioma … performance of the recurrent malignant glioma market
• Historical, current … across the recurrent malignant glioma market
• Reimbursement …
-
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
18 Dec 2023 13:13 GMT
… ;), for the treatment of malignant glioma. This is the world… gene therapy product for malignant glioma to receive FDA ODD … is virtually inevitable for malignant glioma and there is no … -aav-gene-therapy-for-malignant-glioma-granted-orphan-drug-designation- …
-
Neuexcell's NXL-004 gets US orphan status for malignant glioma
18 Dec 2023 17:13 GMT
-
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
07 Nov 2023 14:15 GMT
… Activity in Models of Malignant Glioma
Data Suggests Benefits of … targeted STAT3 Antisense Oligonucleotides Sensitizes Malignant Glioma to PD1-specific Immunotherapy”. … Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade …
-
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
08 Aug 2023 12:00 GMT
… candidate, for the treatment of malignant glioma.
“Malignant glioma is one of the most …
-
Erasca granted FDA Orphan Drug Designation for malignant glioma treatment
27 Jun 2023 16:12 GMT
… -801 for the treatment of malignant glioma, which includes glioblastoma (GBM).
ERAS …
-
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
22 Jun 2023 20:01 GMT
… -801 for the treatment of malignant glioma, which includes glioblastoma (GBM). ERAS … -801 for the treatment of malignant glioma, which includes glioblastoma. About THUNDERBBOLT …